REGENXBIO Inc. (RGNX)
RGNX Stock Price Chart
Explore REGENXBIO Inc. interactive price chart. Choose custom timeframes to analyze RGNX price movements and trends.
RGNX Company Profile
Discover essential business fundamentals and corporate details for REGENXBIO Inc. (RGNX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Sept 2015
Employees
353.00
Website
https://www.regenxbio.comCEO
Curran M. Simpson
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Financial Timeline
Browse a chronological timeline of REGENXBIO Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Mar 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$1.38, while revenue estimate is $24.94M.
Earnings released on 7 Aug 2025
EPS came in at -$1.38 falling short of the estimated -$1.13 by -22.12%, while revenue for the quarter reached $21.36M , missing expectations by -80.59%.
Earnings released on 12 May 2025
EPS came in at $0.12 falling short of the estimated $0.41 by -70.73%, while revenue for the quarter reached $89.01M , missing expectations by -15.51%.
Earnings released on 13 Mar 2025
EPS came in at -$1.01 surpassing the estimated -$1.27 by +20.47%, while revenue for the quarter reached $21.21M , missing expectations by -10.51%.
Earnings released on 6 Nov 2024
EPS came in at -$1.17 falling short of the estimated -$1.16 by -0.86%, while revenue for the quarter reached $24.20M , beating expectations by +3.20%.
Earnings released on 1 Aug 2024
EPS came in at -$1.05 surpassing the estimated -$1.29 by +18.60%, while revenue for the quarter reached $22.30M , missing expectations by -8.36%.
Earnings released on 8 May 2024
EPS came in at -$1.38 falling short of the estimated -$1.28 by -7.81%, while revenue for the quarter reached $15.62M , missing expectations by -33.58%.
Earnings released on 27 Feb 2024
EPS came in at -$1.43 falling short of the estimated -$1.27 by -12.60%, while revenue for the quarter reached $22.21M , missing expectations by -34.67%.
Earnings released on 8 Nov 2023
EPS came in at -$1.41 surpassing the estimated -$1.44 by +2.08%, while revenue for the quarter reached $28.91M , missing expectations by -19.88%.
Earnings released on 2 Aug 2023
EPS came in at -$1.66 falling short of the estimated -$1.26 by -31.75%, while revenue for the quarter reached $19.98M , missing expectations by -42.10%.
Earnings released on 3 May 2023
EPS came in at -$1.53 falling short of the estimated -$1.52 by -0.66%, while revenue for the quarter reached $19.14M , missing expectations by -37.46%.
Earnings released on 28 Feb 2023
EPS came in at -$1.38 surpassing the estimated -$1.48 by +6.76%, while revenue for the quarter reached $31.35M , missing expectations by -16.30%.
Earnings released on 3 Nov 2022
EPS came in at -$1.75 falling short of the estimated -$1.55 by -12.90%, while revenue for the quarter reached $26.51M , missing expectations by -13.96%.
Earnings released on 3 Aug 2022
EPS came in at -$1.58 falling short of the estimated -$1.44 by -9.72%, while revenue for the quarter reached $32.65M , beating expectations by +15.31%.
Earnings released on 4 May 2022
EPS came in at -$1.62 falling short of the estimated -$1.29 by -25.58%, while revenue for the quarter reached $22.22M , missing expectations by -18.37%.
Earnings released on 1 Mar 2022
EPS came in at $6.67 surpassing the estimated $4.71 by +41.61%, while revenue for the quarter reached $398.66M , missing expectations by -6.82%.
Earnings released on 2 Nov 2021
EPS came in at -$1.37 falling short of the estimated -$0.87 by -57.47%, while revenue for the quarter reached $30.77M , missing expectations by -2.28%.
Earnings released on 9 Aug 2021
EPS came in at -$1.36 falling short of the estimated -$1.08 by -25.93%, while revenue for the quarter reached $22.04M , missing expectations by -24.07%.
Earnings released on 5 May 2021
EPS came in at -$1.20 falling short of the estimated -$1.13 by -6.19%, while revenue for the quarter reached $18.88M , missing expectations by -18.71%.
Earnings released on 1 Mar 2021
EPS came in at -$1.24 falling short of the estimated $1.11 by -211.71%, while revenue for the quarter reached $21.45M , missing expectations by -65.13%.
Earnings released on 4 Nov 2020
EPS came in at $0.23 surpassing the estimated -$0.89 by +125.84%, while revenue for the quarter reached $98.91M , missing expectations by -65.19%.
RGNX Stock Performance
Access detailed RGNX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.